+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07160725

Phase 12a Open-Label Study Evaluating BMS-986517 Alone or with Other Treatments in Adults with Advanced Solid Tumors

Led by Bristol-Myers Squibb · Updated on 2026-08-11

540

Participants Needed

20

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and tolerability of BMS-986517 in adults with advanced solid tumors in this phase 12a, first-in-human, open-label study. The trial aims to assess BMS-986517 alone or in combination with other treatments for various solid tumors including non-small cell lung cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, and hormone receptor-positive breast cancer. This study is sponsored by Bristol-Myers Squibb and focuses on treatment outcomes in participants with measurable disease. Participants receive BMS-986517 as a study drug in specified doses on specified days. The study includes multiple parts monotherapy dose escalation, combination dose escalation, monotherapy pharmacodynamics sub-study, monotherapy dose expansion cohorts, and combination dose expansion cohorts. Some parts evaluate BMS-986517 alone, while others combine it with Pumitamig or other treatments. The study design is randomized and sequential, assessing different dose levels and combinations. During the trial, participants undergo regular monitoring for adverse events up to approximately two years, including serious adverse events, dose-limiting toxicities, treatment discontinuations, and deaths related to the study drug. Effectiveness is evaluated through objective response rate and duration of response over about three years. Additional assessments include pharmacokinetic measurements and monitoring of anti-drug antibodies. Participants are followed throughout treatment and post-treatment to assess safety and treatment impact.

CONDITIONS

Brief Title

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

Research Team

B

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

F

First line of the email MUST contain NCT # and Site #.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here